MISSISSAUGA, ONTARIO--(Marketwire - April 02, 2008) - BioSyent Inc. (“BioSyent”) (TSX VENTURE: RX) today released a summary of its 2007 financial results. For the twelve months ending December 31, 2007, sales decreased from $1,514,491 in 2006 to $1,104,325 in 2007. In 2006 total sales registered a high due to the confluence of favourable climatic and market conditions. 2007 sales reflect a higher plateau as compared to years prior to 2006. Sales for FeraMAX™ were modest in 2007 as it was not yet listed on various formularies, restricting its reimbursement.
